Weekly Cisplatin Plus Radiation for Postoperative Head and Neck Cancer (JCOG1008): A Multicenter, Noninferiority, Phase II/III Randomized Controlled Trial.
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
ISSN: 1527-7755
Titre abrégé: J Clin Oncol
Pays: United States
ID NLM: 8309333
Informations de publication
Date de publication:
20 06 2022
20 06 2022
Historique:
pubmed:
2
3
2022
medline:
18
6
2022
entrez:
1
3
2022
Statut:
ppublish
Résumé
The standard treatment for postoperative high-risk locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) is chemoradiotherapy with 3-weekly cisplatin (100 mg/m In this multi-institutional open-label phase II/III trial, patients with postoperative high-risk LA-SCCHN were randomly assigned to receive either chemoradiotherapy with 3-weekly cisplatin (100 mg/m Between October 2012 and December 2018, a total of 261 patients were enrolled (3-weekly cisplatin, 132 patients; weekly cisplatin, 129 patients). At the planned third interim analysis in the phase III part, after a median follow-up of 2.2 (interquartile range 1.19-3.56) years, chemoradiotherapy with weekly cisplatin was noninferior to 3-weekly cisplatin in terms of overall survival, with a hazard ratio of 0.69 (99.1% CI, 0.374 to 1.273 [< 1.32], one-sided Chemoradiotherapy with weekly cisplatin is noninferior to 3-weekly cisplatin for patients with postoperative high-risk LA-SCCHN. These findings suggest that chemoradiotherapy with weekly cisplatin can be a possible treatment option for these patients.
Identifiants
pubmed: 35230884
doi: 10.1200/JCO.21.01293
pmc: PMC9197353
doi:
Substances chimiques
Cisplatin
Q20Q21Q62J
Types de publication
Clinical Trial, Phase II
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1980-1990Commentaires et corrections
Type : CommentIn
Type : CommentIn
Type : CommentIn
Références
Int J Radiat Oncol Biol Phys. 1996 Dec 1;36(5):999-1004
pubmed: 8985019
Head Neck. 2005 Oct;27(10):843-50
pubmed: 16161069
Head Neck. 2019 Aug;41(8):2492-2499
pubmed: 30856297
Int J Radiat Oncol Biol Phys. 1997 Mar 1;37(4):777-82
pubmed: 9128951
Acta Oncol. 2008;47(8):1513-8
pubmed: 18607863
Asia Pac J Clin Oncol. 2011 Sep;7(3):287-92
pubmed: 21884441
Clin Cancer Res. 2021 Aug 1;27(15):4186-4194
pubmed: 34083231
Radiat Oncol. 2019 Feb 11;14(1):32
pubmed: 30744643
J Natl Cancer Inst. 2019 May 1;111(5):490-497
pubmed: 30239887
Br J Radiol. 2017 Nov;90(1079):20170442
pubmed: 29053029
Jpn J Clin Oncol. 2011 Aug;41(8):980-6
pubmed: 21715362
Head Neck. 2016 Apr;38 Suppl 1:E2151-8
pubmed: 25735803
J Clin Oncol. 2018 Apr 10;36(11):1064-1072
pubmed: 29220295
Ann Oncol. 2010 Nov;21(11):2272-2277
pubmed: 20427350
Radiat Oncol. 2012 Dec 18;7:215
pubmed: 23245290
Oncologist. 2017 Sep;22(9):1056-1066
pubmed: 28533474
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):365-73
pubmed: 15380568
Jpn J Clin Oncol. 2012 Oct;42(10):927-33
pubmed: 22923484
N Engl J Med. 1999 Apr 15;340(15):1154-61
pubmed: 10202166
J Clin Oncol. 2004 Dec 1;22(23):4657-9
pubmed: 15534361
J Clin Oncol. 2002 Apr 15;20(8):2038-44
pubmed: 11956263
Clin Oncol (R Coll Radiol). 2011 Mar;23(2):134-40
pubmed: 21030225
Oral Oncol. 2016 Aug;59:43-49
pubmed: 27424181
Int J Radiat Oncol Biol Phys. 2012 Dec 1;84(5):1198-205
pubmed: 22749632
Jpn J Clin Oncol. 2007 Oct;37(10):725-9
pubmed: 17925299
N Engl J Med. 2004 May 6;350(19):1937-44
pubmed: 15128893
J Clin Oncol. 2007 Nov 1;25(31):5019-23
pubmed: 17971602
N Engl J Med. 2004 May 6;350(19):1945-52
pubmed: 15128894
Medicine (Baltimore). 2018 May;97(21):e10778
pubmed: 29794758